RESOURCES | Data Updates | Securities

CRB Monitor Securities Database Updates

During the week of May 9 - 15, 2022, CRB Monitor’s research team made several updates to securities and added source documents and relevant news articles to the CRB Monitor database.

Summary of the updates for the Week of May 9 - 15, 2022:

• Added 1 Tier 1B Security:
  • +1 = CRB Tier Upgraded to 1B (“Skye Bioscience, Inc.”)
    • Rationale = Skye Bioscience, Inc. entered into an agreement to acquire all of the issued and outstanding shares of publicly-traded Tier 1B CRB "Emerald Health Therapeutics, Inc." Emerald Health is a Vancouver-based Canadian licensed cannabis producer which is pivoting into the pharmaceutical sector. Skye Bioscience now qualifies for Tier 1B given that it intends to acquire another Tier 1B CRB.
• Removed 2 Tier 2 Securities:
  • -1 = CRB Tier Upgraded to 1B (“Skye Bioscience, Inc.”)
  • -1 = CRB Tier Downgraded to Tier 3 (“BetterLife Pharma Inc.”)
• Added 1 Tier 3 Security:
  • +1 = CRB Tier Downgraded to Tier 3 (“BetterLife Pharma Inc.”)
    
    • Rationale = BetterLife Pharma Inc. previously operated in the cannabis industry through its "Pivot" subsidiaries ("Pivot Naturals", "Pivot Pharmaceuticals Manufacturing", & "Pivot Green Stream Health Solutions") whereby it conducted research, development and commercialization of cannabinoid-based nutraceuticals/pharmaceuticals. However, these subsidiaries have since been divested/dissolved. At this point in time, BetterLife Pharma's only connection to the cannabis industry is through other platform technologies related to cannabis which it still owns. These technologies include various cannabis delivery platforms, methods, and devices. Per its own admission, BetterLife Pharma is "assessing how best to proceed with these technologies." This involvement in the cannabis industry not constitute a substantial revenue source, relative to its overall operations. Given this, BetterLife Pharma now qualifies for Tier 3.

All newly-identified CRBs during the week: